Wedbush lowered its price target for Nektar Therapeutics shares from $50 to $40, maintaining a Neutral rating, following the company's Q3 2026 financial results. This adjustment reflects the reported quarterly revenue of $9.39 million and a net loss of $1.63 per share, indicating a less optimistic outlook from the analyst firm.
Wedbush's decision to cut Nektar Therapeutics' price target from $50 to $40, while keeping a Neutral rating, stems directly from the company's Q3 2026 financial performance. The reported revenue of $9.39 million and a net loss of $1.63 per share likely fell short of Wedbush's previous expectations, leading to a downward revision of their valuation model. This is significant for NKTR investors as it signals a more cautious outlook from a prominent analyst, potentially influencing short-term investor sentiment and putting downward pressure on the stock. The long-term implications depend on Nektar's ability to improve its financial performance and pipeline progress, but in the short term, this analyst downgrade represents a key risk for traders holding NKTR shares.